Figure 1A.



SEQ ID NO:
18 LPAPKNLVVSEVTEDSLRLSWADP-HGFYDSFLIQYQESEKVGEAINLTVPGSERSYDLTG (60)
19 LPAPKNLVVSEVTEDSLRLSWTYD-RDGYDSFLIQYQESEKVGEAINLTVPGSERSYDLTG
20 LPAPKNLVVSEVTEDSLRLSWGYN-GDHFDSFLIQYQESEKVGEAINLTVPGSERSYDLTG
21 LPAPKNLVVSEVTEDSLRLSWDDP-RGFYESFLIQYQESEKVGEAINLTVPGSERSYDLTG
22 LPAPKNLVVSEVTEDSLRLSWTWP-YADLDSFLIQYQESEKVGEAINLTVPGSERSYDLTG
23 LPAPKNLVVSEVTEDSLRLSWGYN-GDHFDSFLIQYQESEKVGEAINLTVPGSERSYDLTG
24 LPAPKNLVVSEVTEDSLRLSWDYDLGDHFDSFLIQYQESEKVGEAINLTVPGSERSYDLTG
25 LPAPKNLVVSEVTEDSLRLSWDDP-WAFYESFLIQYQESEKVGEAINLTVPGSERSYDLTG
27 LPAPKNLVVSEVTEDSARLSWDDP-WAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG
29 LPAPKNLVVSEVTEDSLRLSWTWP-YADLDSFLIQYQESEKVGEAINLTVPGSERSYDLTG
107 LPAPKNLVVSEVTEDSARLSWADP-HGFYDSFLIQYQESEKVGEAIVLTVPGSERSYDLTG
108 LPAPKNLVVSEVTEDSARLSWDDP--WAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG
109 LPAPKNLVVSEVTEDSARLSWDDP--HAFYESFLIQYQESEKVGEAIVLTVPGSERSYDLTG
110 LPAPKNLVVSEVTEDSARLSWADP--HGFYDSFLIQYQESEKVGEAIVLTVPGSERSYDLTG
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT (94)
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAIFTT
LKPGTEYTVSIYGVHNVYKDTNMRGLPLSAEFTT
LKPGTEYTVSIYGVHNVYKDTNIRGLPLSAIFTT
LKPGTEYTVSIYGVHNVYKDTNIRGLPLSAIFTT
LKPGTEYTVSIYGVHNVYKDTNIRGLPLSAIFTT

Figure 1B

```
SEQ ID
NO:
26    LPAPKNLVVSEVTEDSLRLSWTAP-DAAFDSFLIQYQESEKVGEAINLTVPGSERSYDLTG   (60)
28    LPAPKNLVVSEVTEDSARLSWTAP-DAAFDSFLIQYQESEKVGEAIVLTVPGSERSYDLTG
      ************ ****.********** ********** ****************

26    LKPGTEYTVSIYGVLGSYVTEHDVMLPLSAEFTT                            (94)
28    LKPGTEYTVSIYGVLGSYVTEHDVMLPLSAIFTT
      ********************** **** ***
```

Figure 2.

```
                    A      AB   B     BC
TENCON27  (1)   LPAPKNLVVSRVTEDSARLSWTAPDAAEDS   (30)
TCL14     (1)   LPAPKNLVVSRVTEDSARLSWTAPDAAFDS   (30)

                    C      CD     D    DE   E
TENCON27  (31)  FLIQYQESEKVGEAIVLTVPGSERSYDLTG   (60)
TCL14     (31)  FXIXYXEXXXXGEAIVLTVPGSERSYDLTG   (60)

                    EF     F      FG     G
TENCON27  (61)  LKPGTEYTVSIYGVKGGHRSNPLSAIFTT   (89)
TCL14     (61)  LKPGTEYXVXIXGVKGGXXSXPLSAIFTT   (89)
```

Figure 3.


SEQ ID
NO:
32 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYDEVVVGGEAIVLTVPGSERSYDLTG (60)
33 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFFIRYDEFLRSGEAIVLTVPGSERSYDLTG
34 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
35 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
36 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFVIRYFEFLGSGEAIVLTVPGSERSYDLTG
37 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYLEFLLGGEAIVLTVPGSERSYDLTG
38 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
39 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTD
40 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
41 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
42 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
43 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
44 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
45 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
46 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
47 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFTTAGEAIVLTVPGSERSYDLTG
48 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFELLSTGEAIVLTVPGSERSYDLTG
49 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFVSKGEAIVLTVPGSERSYDLTG
111 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG
112 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFVGSGEAIVLTVPGSERSYDLTG
113 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFVSKGDAIVLTVPGSERSYDLTG
114 LPAPKNLVVSRVTEDSARLSWTAPDAAEDSFWIRYFEFLGSGEAIVLTVPGSERSYDLTG

Figure 3 (continued)

```
SEQ ID
NO:

32              LKPGTEYYVNILGVKGGSISVPLSAIFTT          (89)
33              LKPGTEYWVTILGVKGGLVSTPLSAIFTT
34              LKPGTEYIVNIMGVKGGSISHPLSAIFTT
35              LKPGTEYVVNILGVKGGGLSVPLSAIFTT
36              LKPGTEYVVQILGVKGGYISIPLSAIFTT
37              LKPGTEYVVQIMGVKGGTVSPPLSAIFTT
38              LKPGTEYVVGINGVKGGYISYPLSAIFTT
39              LKPGTEYGVTINGVKGGRVSTPLSAIFTT
40              LKPGTEYVVQIIGVKGGHISLPLSAIFTT
41              LKPGTEYVVNIMGVKGGKISPPLSAIFTT
42              LKPGTEYAVNIMGVKGGRVSVPLSAIFTT
43              LKPGTEYVVQILGVKGGSISVPLSAIFTT
44              LKPGTEYVVNIMGVKGGSISYPLSAIFTT
45              LKPGTEYVVQILGVKGGYISIPLSAIFTT
46              LKPGTEYVVQIMGVKGGTVSPPLSAIFTT
47              LKPGTEYVVNIMGVKGGSISPPLSAIFTT
48              LKPGTEYVVNIMGVKGGSISPPLSAIFTT
49              LKPGTEYVVNIMGVKGGSISPPLSAIFTT
111             LKPGTEYVVNILGVKGGKISPPLSAIFTT
112             LKPGTEYVVNILGVKGGSISPPLSAIFTT
113             LKPGTEYVVNILGVKGGSISPPLSAIFTT
114             LKPGTEYVVNILSVKGGSISPPLSAIFTT
                ******** * *  .**** :* ********
```




anti-EGFR Centyrin (83v2)
anti-c-Met Centyrin (A5)
Mixture
Bispecific Centyrin
Relative pMet (RCLU)
40000
30000
20000
10000
0
0.1
1
10
100
1000
10000
100000
Biologic (nM)

Figure 4.

Figure 5.



	Bispecific Centyrin (17-A3)	anti-EGFR Centyrin (17)
IC50	76.64	150.8

	Bispecific Centyrin (83-H9)	anti-c-Met Centyrin (H9)
IC50	1.676	227.0

	Bispecific Centyrin (17-A3)	anti-EGFR Centyrin (17)
IC50	83.24	35.44

	Bispecific Centyrin (83-H9)	anti-c-Met Centyrin (H9)
IC50	0.07890	80.83

	Bispecific Centyrin (17-A3)	anti-EGFR Centyrin (17)
IC50	2.296	70.16

Figure 6.




pMet
pEGFR
pERK1/2
1500
1000
500
0
8000
6000
4000
2000
0
10500
9000
7500
6000
4500
3000
1500
0
PBS
PBS
EGFR - 83 83 17 17 - 83 83 17 17
cMet - A3 A5 A3 A5 - A3 A5 A3 A5
6 hours
72 hours
* p<0.01

Figure 7.


6h
72h
Plasma accumulation (%ID)
Tumor accumulation (%ID/g)
0
50
100
150
200
5
10
15
20
83v2-A5-ABD
83v2-A3-ABD
17v2-A5-ABD
17v2-A3-ABD



Mean Tumor Vol (cu mm +/- SEM)
1200
1000
800
600
400
200
0
1
6
9
13
16
20
23
27
30
34
37
38
41
Day of Study
Dosed 3x/wk i.p. from Day 1 to 20
PBS
high EGFR-high c-Met
high EGFR-med c-Met
med EGFR-high c-Met
med EGFR-med-c-Met

Figure 8.



H292-HGF Human Lung Cancer Xenograft Model
Vehicle 10 uL/g QDx3 weeks i.p.
Bispecific Centyrin 25mg/kg 10 uL/g 3 times/week x3 weeks i.p.
Crizotinib 30 mg/kg 10 uL/g QDx17 days p.o.
Erlotinib 50 mg/kg 10 uL/g QDx3 weeks p.o.
Crizotinib; Erlotinib 50 mg/kg; 50 mg/kg 10 uL/g QDx3 weeks, QDx3 weeks p.o.
Cetuximab 1 mg/mouse 0.2ml/mouse Q4d*6 i.p.
Tumor Size(mm3)
3600
3200
2800
2400
2000
1600
1200
800
400
0
6
8
10
12
14
16
18
20
22
24
26
28
30
32
34
36
38
40
42
Days after Tumor Inoculation
G1, G4 and G5
G3
G2
G6

Figure 9.